A Prospective, Randomized, Controlled, Multi-center Clinical Trial of Surufatinib Combined With Gemcitabine and Nab-paclitaxel Versus Gemcitabine Combined With Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
To explore the efficacy and safety of surufatinib in combination with AG regimen verus AG regimen as peri-operative treatment in high - risk resectable or borderline resectable pancreatic cancer
• Histologically or cytologically confirmed high-risk resectable or borderline resectable pancreatic cancer;
• 18-75 years old (including 18 and 75 years old);
• No BRCA1/2 or PALB2 mutation;
• No previous pancreatic cancer resection, systemic therapy, or local radiation therapy;
• Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
• Life expectancy ≥ 6 months;
• At least one measurable lesion according to RECIST version 1.1;
• Adequate organ and bone marrow functions;
• Women of childbearing age need to take effective contraceptive measures.